The Risks of Cytokine Storms

CRS is a syndrome that gets triggered by activation of T cells when they engage the CAR, the chimeric antigen receptor with the antigens expressed by the tumor cells. It usually picks around 2 to 7 days after infusion, can still present up to 3 weeks after CAR T. The ASTCT has guidelines published in 2019 that offer a consensus grading system for CRS. Management depends on the grade, and usually involves Tossilismab, which is now a very famous anti-interleukin 6 monoclonal antibody.